Lilly/AstraZeneca's Lanabecestat Becomes Latest BACE Inhibitor Casualty
Just weeks after Johnson & Johnson halted development of its BACE inhibitor for Alzheimer's and a few months after Merck & Co failed at Phase III, Lilly and AstraZeneca end trials of lanabecestat.
You may also be interested in...
Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.
An interim look at two Phase II/III trials showed the drug worsened cognition in people at high risk of developing Alzheimer's disease. This is the 16th failure of a BACE-targeting therapy.
Elenbecestat can continue in the Phase III MISSION AD studies in Alzheimer’s, the data safety monitoring board says.